Summary Four poly(ADP-ribose) polymerase (PADPRP) inhibitors [3-aminobenzamide, benzamide, 3,4-dihydro-5-methoxyisoquinolin-1(2H)-one (PD 128763) and 8-hydroxy-2-methylquinazolin-4(3H)-one (NU1025)] were compared with respect to their effects on a number of biological end points. The following parameters were assessed: their ability to inhibit the enzyme in permeabilised L1210 cells; their ability to potentiate the cytotoxicity of temozolomide (including the cytotoxicity of the compounds per se); their ability to increase net levels of temozolomide-induced DNA strand breaks and inhibit temozolomide-induced NAD depletion. PD 128763 and NU1025 were equipotent as PADPRP inhibitors, and 40-and 50-fold more potent than benzamide and 3-aminobenzamide respectively. All the compounds acted in a concentration-dependent manner to potentiate the cytotoxicity and increase DNA strand break levels in cells treated with temozolomide. There was an excellent correlation between the potency of the compounds as PADPRP inhibitors and their effects on cell survival and DNA repair. Temozolomide treatment caused a decrease in cellular NAD levels, and this was abolished by the PADPRP inhibitors. In conclusion, the new generation of PADPRP inhibitors are at least 50-fold more effective than 3-aminobenzamide as chemopotentiators, and can be used at micromolar rather than millimolar concentrations in intact cells.
Poly(ADP-ribose) polymerase (PADPRP, EC 2.4.2.30) is an abundant chromatin-bound enzyme which is activated by DNA strand breaks. PADPRP function has been implicated in a variety of biological processes, including DNA repair and cellular survival following DNA damage, recombination and regulation of gene expression and development (for reviews see Boulikas, 1991; de Murcia and Menissier-de Murcia, 1994) . Although the role of PADPRP is best understood in DNA repair, this is still an area of contention regarding the precise molecular mechanisms involved. Two general mechanisms have been proposed, based on accumulated evidence. Poly(ADP-ribose) synthesis leads to a dramatic structural modification of chromatin, resulting from the electrostatic repulsion of the negatively charged covalently modified proteins (mainly PADPRP itself and histones) from the DNA. This may allow access of repair enzymes to damaged sites on DNA (Althaus et al., 1993) . Alternatively, unmodified PADPRP binds tightly to free DNA ends, thus preventing further processing; upon automodification, PAD-PRP is released from DNA, allowing gap filling and ligation to occur (Satoh and Lindahl, 1992 ). An additional function of poly(ADP-ribose) synthesis may be to modulate directly the activity or function of covalently modified acceptor proteins (enzymes, transcription factors). For example, poly (ADP-ribosylation) of DNA polymerases, ligase and topoisomerase I causes inhibition of these enzymes in vitro (Ferro et al., 1983; Yoshihara et al., 1985) . However, little work has been carried out to establish whether these proteins can act as acceptors in intact cells.
A range of PADPRP inhibitors, of which 3-aminobenzamide (3AB) has been the most widely used, was first developed by Purnell and Whish (1980) . The demonstration that they could modulate cellular DNA repair and survival responses (Durkacz et al., 1980) al., 1992) . There has been a long-standing dispute concerning the specificity of benzamide and its derivatives as PADPRP inhibitors (particularly regarding their effects on de novo purine synthesis), and thus about the interpretation of the biological data (e.g. Hunting et Moses et al., 1990) . Nevertheless, the literature spanning 15 years portrays a remarkable consistency regarding their effects. Thus, PADPRP inhibitors, at concentrations which are not cytotoxic per se, inhibit ADP-ribose polymer synthesis in intact cells (Rankin et al., 1989) . They retard the rejoining of DNA strand breaks and potentiate the cytotoxicity of a range of DNA-damaging agents (e.g. Durkacz et al., 1980) . PADPRP activation by DNA strand breaks causes cellular NAD depletion which is abrogated by PADPRP inhibitors (Durkacz et al., 1980) . The increased levels of DNA strand breaks obtained in the presence of PADPRP inhibitors has been assumed to be a consequence of inhibition of a late stage in the repair process (e.g. ligation, Creissen and Shall, 1982) .
In more recent years, this scenario of events modulated by PADPRP function following DNA damage has been further substantiated by molecular, genetic and in vitro approaches to PADPRP function. Mutant cell lines which are deficient in PADPRP activity have been isolated by a number of different techniques (Maclaren et al., 1990; Chatterjee et al., 1991; Witmer et al., 1994) . These cell lines are typified by their hypersensitivity to monofunctional alkylating agents. Cell lines transfected with and overproducing the 'DNA binding domain' (DBD) of PADPRP, thus inhibiting endogenous PADPRP activation, are also hypersensitive to monofunctional alkylating agents, and are unable to carry out unscheduled DNA synthesis (Molinette et al., 1993) . Similar results have been obtained by reducing endogenous PADPRP synthesis by the use of antisense olignucleotides to PADPRP (Smulson et al., 1994) . Finally, elegant in vitro experiments using crude cell extracts which can carry out DNA repair have established that PADPRP, in the absence of substrate, blocks DNA strand breaks snd prevents subsequent steps leading to religation of the DNA (Satoh and Lindhal, 1992; Satoh et al., 1993) .
PADPRP inhibitors have the potential to act as resistance modifiers when used in conjunction with radiation or chemotherapeutic agents. However, very little in vivo work has been carried out to assess their capacity to increase the therapeutic index of anti-cancer drugs, mainly because benzamide and its derivatives lacked sufficient potency and were of low solubility. Recently, more potent PADPRP inhibitors have been identified (e.g. Suto et al., 1991) , but limited work has been carried out to establish their biological efficacy.
We have developed an evaluation system to compare candidate compounds with respect to their potency as PADPRP inhibitors and their effectiveness as chemopotentiators in intact cells. Two 'classical' inhibitors, benzamide (BZ) and 3AB, have been compared with 3,4-dihydro-5-methoxyisoquinolin-1(2H)-one (PD 128763), developed by Warner Lambert (Suto et al., 1991) , and 8-hydroxy-2-methylquinazolin-4(3H)-one (NU1025). NU1025 was synthesised in the Department of Chemistry, University of Newcastle upon Tyne (Griffin et al., 1995) , as part of an ongoing programme to design new PADPRP inhibitors. PD 128763 (100 mg kg-') has been shown to be a highly active radiosensitiser in vivo, causing > 50% reduction in tumour burden in mice bearing subcutaneous implants of SCC7 cells (Leopold and SeboltLeopold, 1992) . The structures of the PADPRP inhibitors are shown in Figure 1 for comparison.
A chemotherapeutically relevant alkylating agent, temozolomide (TM, see Figure 1 for structure; Stevens et al., 1987) , which has shown promising results in phase I clinical trials (Newlands et al., 1992) , was used in these studies. TM breaks down in biological milieu to MTIC [5-(3-methyl- triazen-1-yl)imidazole-4-carboxamide], and thence to the methyldiazonium ion, which directly methylates bases in DNA (Denny et al., 1994) .
In the body of work described here, we have used TM, in conjunction with the PADPRP inhibitors, to investigate the PADPRP-mediated repair and survival responses in murine leukaemia L1210 cells. The results demonstrate an excellent correlation between in vitro potency of the compounds as PADPRP inhibitors, and their ability to modulate cellular responses induced by DNA damage. Cell culture, growth inhibition and clonogenic survival assays The murine leukaemia L1210 cell line was maintained as a suspension culture in RPMI-1640 medium supplemented with 10% fetal calf serum, glutamine (2 mM) and antibiotics (penicillin, 100 U ml-'; streptomycin, 100 fig ml 1). Hepes and sodium bicarbonate were added at final concentrations of 18 mM and 11 mM respectively. Cell densities were routinely maintained between 1 x 104 and 8 x 105 ml-'. Growth inhibition experiments were used to assess the cytostatic effects of the compounds. Cells were seeded at 1 x I04ml-' in triplicate in 24-well multidishes. After 24 h drugs were added in the combinations and at the concentrations specified in the figure legends. At this time one set of replicates was counted using a Coulter counter (No) . After 48 h the remaining samples were counted (N,). The percentage growth inhibition of drug-treated samples was estimated as N, -No (drug treated)/N,-No (control) x 100. In drug combination experiments, in which evidence of synergistic effects on cell growth or clonogenicity (see below) was being sought, the single, fixed concentration drug sample was taken as the control value (N, control) in the above equation.
Clonogenic survival assays were used to assess the cytotoxicity of the compounds. They were performed as previously described (Sebolt-Leopold and Scavone, 1992) NAD assays Cellular NAD levels were determined by a modification of the method of Nisselbaum and Green (1969) . Cells were treated with drugs at the concentrations and for the times specified in the figure legends. Approximately 5 x 106 cells per sample were harvested at 4°C, washed once with ice-cold phosphate-buffered saline (PBS) and repelleted. The pellet was resuspended in 1.0 ml of 50% (v/v) ethanol and sonicated for 20 s. An aliquot was removed for protein estimation (Bradford, 1976) , and then the suspension was centrifuged for 2 min in a microfuge. The supernatant liquid was used for NAD assays as described. Results are expressed as pmol NAD mg-I protein, and represent the average of three independent samples ± s.e. DNA strand break assays DNA strand-break levels were assessed using the technique of Kohn et al. (1981) . Cells were prelabelled with 0.4 yCi ml-' [14C]TdR for 24 h, followed by a 6 h chase in Potentadon of temozolomWe cytotoxcity S Boulton et al 851 non-radioactive medium. Cells were then exposed to drugs at the concentrations and for the times specified in the figure legends. Internal standards were similarly labelled with 1 lsCi ml -[3H]TdR, exposed to 300 cGy, then loaded on the same filters as the drug treated samples, and eluted at pH 12.2. To summarise the data obtained, the results were expressed using the 'relative elution' (RE) formula of Fornace and Little (1977) . RE represents the amount of DNA from the treated samples retained on the filter as a ratio of control (untreated). It is calculated using (log RR,p,k) -(log RRcontroj), where RR (relative retention) is the fraction of sample DNA retained on the filter when 50% of the internal standard DNA has eluted. Points represent six replicates from three individual experiments ± s.e.
Results

PADPRP assays
The relative potencies of the four compounds studied as inhibitors of PADPRP are shown in Figure 2 [NU10251 (mM) [PD 1287631 (mM) Figure 3 The effect of increasing concentrations of PADPRP inhibitors alone (0) or in conjunction with a fixed (100 gM) concentration of TM (0) [Inhibitor] (mM) Figure 5 The effect of TM and the PADPRP inhibitors on the cellular NAD levels. (a) Changes in NAD levels are a convenient, albeit indirect, assessment of PADPRP activation in TM-treated cells. Figure 5a shows a time-dependent depletion of NAD levels following treatment with 1 or 2 mM TM. Evidence that the NAD depletion is mediated by PADPRP activation is shown in Figure Sb . A 4 h incubation with 2 mM TM caused a 50% decrease in cellular NAD levels, and this was abrogated in a concentration-dependent manner by PD 128763 and 3AB.
Note that 10 ILM PD 128763 sufficed to prevent approximately 50% of NAD drop, and that NAD depletion was completely prevented by 100 ItM. These data correlate with the concentration ranges of PD 128763 required to effect potentiation of cytotoxicity in the clonogenic survival experiments. In contrast, at least an order of magnitude higher concentrations of 3AB were required to exert the same effects on NAD levels in TM-treated cells.
DNA strand break assays The effect of the PADPRP inhibitors on DNA strand break levels in TM-treated cells was monitored by alkaline elution. A 1 h treatment with TM resulted in a concentrationdependent increase in the rate of elution (results not shown). Changes in DNA strand break levels were detectable at levels of TM as low as 150 lfM, which reduced survival by about 30%. All the compounds were tested for their ability to produce strand breaks when used alone. A 24 h incubation of cells with 1 mM PD 128763 or NU1025 and 20 mM 3AB or BZ had no effect on DNA strand-break levels compared with untreated cells (results not shown).
Co-incubation of a fixed concentration of TM (150 IM) with increasing concentrations of all PADPRP inhibitors for 1 h caused a progressive increase in the rate of elution compared with TM alone. A specimen elution profile for the effect of increasing concentrations of NU1025 on TMinduced DNA strand break levels is shown in Figure 6 . The results for all four compounds have been summarised by plotting RE values vs inhibitor concentration, and are shown in Figure 7 . Note that the RE values for TM + inhibitortreated cells have been calculated using TM alone controls, and not untreated cells. For all the compounds, the RE value increased linearly with increasing concentration. However, RE values started increasing for PD 128763 and NU1025 at about 100 ylM, whereas concentrations above 3 mm and 5 mM were required to increase significantly the RE values for BZ and 3AB respectively. Again, the potency of the compounds in the DNA strand break assay demonstrated an excellent correlation with in vitro PADPRP inhibitory potency. Finally, the temporal kinetics of TM-induced DNA strandbreak formation and religation was analysed, and the results are presented in Figure 8 . In cells treated with 200 tLM TM, DNA strand-break levels increased rapidly up to 4 h and declined thereafter. By 24 h DNA strand break levels had returned to almost control levels. Both 3AB (5 mM) and NU1025 (300 J.M) increased net levels of DNA strand breaks over the entire time period. The time interval during which DNA strand break levels were highest (approximately 2-4 h) correlated with the reported timing of the peak levels of MTIC obtained in culture medium following addition of TM (Tsang et al., 1991 (10-50I1M) required to potentiate TM cytotoxicity compared with the concentrations of the compounds alone required to exert cytotoxic effects (> 1 mM). In comparison, considerable overlap is evident in the concentrations of 3AB and BZ required to exert these two effects. Thus, there is a bigger gap between the synergistic enhancement of cytotoxicity and the independent toxicity of the new inhibitors compared with 3AB and BZ, indicative of improved specificity.
It has not escaped our notice that the data presented here suggest a dissociation between the effect of PADPRP inhibitors on cell survival and their effect on DNA strand break repair. For example, significant potentiation of TM cytotoxicity is obtained with PD 128763 at 10 9M, and has reached its maximum by 50 gM (see Figure 4) . In contrast, PD 128763 does not affect TM-induced DNA strand break levels significantly until concentrations of > 100 LM are reached (Figure 7) . A plausible explanation for these observations is that PADPRP mediates not only DNA repair processes, but also independently modulates DNA damageinducible responses involved in cell survival (e.g. specific gene transcription, p53 stabilisation; Kastan et al., 1991) . The difference in the concentrations of inhibitors required would reflect the degree of inhibition of PADPRP necessary to modulate these responses. A more detailed analysis of these observations is currently under way.
In conclusion, PD 128763 and NU1025 can potentiate the cytotoxicity of clinically relevant concentrations of TM, and at micromolar compared with millimolar concentrations required for BZ and 3AB. These are important considerations if the use of these compounds as potentiators of druginduced cytotoxicity is to be extrapolated to the clinic. These data provide the groundwork for initiating in vivo studies to establish the ability of PADPRP inhibitors, used in conjunction with chemotherapeutic agents, to enhance tumour regression. Abbreviations 3AB, 3-aminobenzamide; BZ, benzamide; IC", concentration which reduces growth/activity by 50%; DMSO, dimethyl sulphoxide; DBD, DNA-binding domain; DEF1O, dose enhancement factor at 10% survival; LD50, dose which reduces survival by 50% (lethal dose); MTIC, 5-(3-methyl-triazen-1-yl) imidazole-4-carboxamide; PBS, phosphate-buffered saline; PADPRP, poly(ADP-ribose) polymerase; RE, relative elution; RR, relative retention; TM, temozolomide; s.e., standard error.
